Results 311 to 320 of about 10,998,800 (355)
Some of the next articles are maybe not open access.
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Ca-A Cancer Journal for Clinicians, 2021Kyle Wang
exaly
Current trends of targeted therapy for oral squamous cell carcinoma
Journal of Cancer Research and Clinical Oncology, 2022Hongjiao Li +3 more
semanticscholar +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2014
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis.
openaire +1 more source
Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. It has been shown that rituximab exerts cytotoxic activities through CDC and ADCC, and that it directly induces apoptosis.
openaire +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly
Breast Cancer Therapy–Classical Therapy, Drug Targets, and Targeted Therapy
2014Therapeutic options for breast cancer treatment include chemotherapy, endocrine therapy, and novel targeted therapy. In the adjuvant setting, chemotherapy is indicated for early breast cancer treatment based on tumor stage, histological grading, estrogen and progesterone receptor, proliferative index, and human epidermal growth factor receptor.
openaire +1 more source